论文部分内容阅读
背景与目的观察抗血管生成药物--恩度联合吉西他滨+顺铂方案一线治疗晚期非小细胞肺癌的疗效及毒副反应。方法回顾性分析2006年1月-2008年4月我科收治的85例晚期非小细胞肺癌患者的临床资料,其中吉西他滨+顺铂(GP)方案治疗55例,恩度+吉西他滨+顺铂(GPE)方案治疗30例。以完全缓解、部分缓解、稳定和病情进展为近期疗效评价指标;远期疗效评价指标包括无进展生存时间、中位生存期和1年生存率。评价血液学毒性、消化道反应、心脏毒性等毒副反应。结果GP方案组与GPE方案组的总有效率分别为30.9%和53.3%,差异有统计学意义(P<0.05);无进展生存时间分别为5.8月和6.9月,中位生存期和1年生存率相似,差异无统计学意义(P>0.05)。两组患者的Ⅲ-Ⅳ度中性粒细胞减少和血小板减少发生率、恶心呕吐发生率,差异无统计学意义(P>0.05),但心率失常发生率GP方案组(4.0%)较GPE方案组(9.5%)低,差异有统计学意义(P<0.05)。结论GP方案加用恩度可以提高治疗晚期NSCLC的有效率,延长无疾病进展时间,其毒性可以耐受,但远期疗效有待于进一步观察。
BACKGROUND & AIM: To observe the efficacy and side effects of first-line anti-angiogenic drug-Endo combined with gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods The clinical data of 85 patients with advanced non-small cell lung cancer admitted to our department from January 2006 to April 2008 were retrospectively analyzed. Among them, 55 cases were treated with gemcitabine plus cisplatin (GP) regimen, and Endostar + gemcitabine + cisplatin GPE) regimen in 30 cases. With complete remission, partial remission, stability and progression of the disease as the recent evaluation indicators of efficacy; long-term efficacy evaluation indicators include progression-free survival time, median survival and 1-year survival rate. Evaluation of hematological toxicity, gastrointestinal reactions, cardiac toxicity and other toxic reactions. Results The total effective rates of GP group and GPE group were 30.9% and 53.3%, respectively, with significant difference (P <0.05); progression-free survival time was 5.8 months and 6.9 months respectively, and the median survival time and 1 year The survival rates were similar with no significant difference (P> 0.05). The incidence of Ⅲ-Ⅳ neutropenia and thrombocytopenia and the incidence of nausea and vomiting were not statistically different between the two groups (P> 0.05). However, the rate of arrhythmia in GP group (4.0%) was higher than that in GPE group Group (9.5%), the difference was statistically significant (P <0.05). Conclusions The GP regimen plus endostar can improve the efficiency of treatment of advanced non-small cell lung cancer (NSCLC), prolong the progression-free time, and its toxicity can be tolerated. However, the long-term efficacy remains to be further observed.